Trial · NCT04464122
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
NCT04464122, Recruiting, University of Roma La Sapienza
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN). Trials, record NCT04464122. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04464122
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
- NCT number
- NCT04464122
- Status
- Recruiting
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Roma La Sapienza
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Carcinoma
- Interventions
- Somatostatin analog; chemotherapy
- First posted
- 2020-07-09
- Last updated
- 2025-04-03
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the modification of the angiogenetic mediator sTie2 after treatment. | baseline - + 1 month - +3 months | Modification of sTie (soluble Tie2) after treatment |
| Secondary | To evaluate the difference in the angiogenetic mediator sTie2 between patients and controls | baseline | Comparison of basal levels of sTie between patients and controls |
| Secondary | To validate the use of circular RNAs from TEPs in NEN diagnosis | baseline | Validation of the use of circular RNAs sequencing from tumor educated platelets (TEPs) in NETs diagnosis, through the comparison between patients and controls |
| Secondary | To evaluate the changing in circular RNAs from TEPs in NEN patients after somatostatin analogs treatment | baseline - + 1 month - +3 months | Modification in circular RNAs sequencing from tumor educated platelets (TEPs) in patients after treatment |
| Secondary | To compare circular and cellular angiogenesis mediators between patients and controls | baseline | Comparison of basal level of other circular and cellular angiogenesis mediators between patients and controls (Angiogenic factors: ANG1, ANG2, FGF1, FGF2, NRP1, NRP2, VEGFA, VEGFB, VEGFC, HIF1A, NOS3, PROK1, PROK2; Cytokines: CCL11, CCL2, CXCL1, CXCL10, CXCL5, CXCL6, CXCL9, IL1B, IL6, TNF; Receptors and other angiogenic factors: VEGFR1, VEGFR2, TIE2, PDGFR, TGFBR, MMP14, MMP2, MMp9, TIMP1, TIMP2, TIMP3, PROKR1, PROKR2) |
| Secondary | To evaluate the changing in circular and cellular angiogenesis mediators after treatment. | baseline - + 1 month - +3 months | Modification of other circular and cellular angiogenesis mediators in patients after treatment (Angiogenic factors: ANG1, ANG2, FGF1, FGF2, NRP1, NRP2, VEGFA, VEGFB, VEGFC, HIF1A, NOS3, PROK1, PROK2; Cytokines: CCL11, CCL2, CXCL1, CXCL10, CXCL5, CXCL6, CXCL9, IL1B, IL6, TNF; Receptors and other angiogenic factors: VEGFR1, VEGFR2, TIE2, PDGFR, TGFBR, MMP14, MMP2, MMp9, TIMP1, TIMP2, TIMP3, PROKR1, PROKR2) |
| Secondary | To quantify PBMC subpopulation in patients and controls | baseline | Quatification of peripheral blood mononuclear cells (PBMC) subpopulations in patients and controls |
| Secondary | To evaluate the modification of PBMC subpopulation in patients after treatment | baseline - + 1 month - +3 months | Modification of peripheral blood mononuclear cells (PBMC) subpopulations in patients after treatment |
| Secondary | To compare classical neuroendocrine markers serum levels between patients and controls | baseline | Comparison of basal serum level of classical neuroendocrine markers (chromogranin a and neuron specific enolase) between patients and controls |
| Secondary | To evaluate the modification of classical neuroendocrine markers in patients after treatment | baseline - + 1 month - +3 months | Modification of classical neuroendocrine markers (chromogranin a and neuron specific enolase) in patients after treatment |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04464122
GET https://conductscience.org/api/trials/v1/NCT04464122/registered